21 August 2019 whitepapers
When different drug products are produced in shared facilities, the potential for cross-contamination is always a concern that needs to be addressed.
21 August 2019 News
Finnish virtual antibiotics developer Northern Antibiotics is working to offer a new molecule targeting bacteria that are resistant to existing drugs.
19 August 2019 Analysis
One year into the latest Ebola outbreak in the DRC, the pharma industry has developed new, better treatments for this deadly virus. However, drugs alone cannot end the outbreak as...
13 August 2019 News
Researchers from Statens Serum Institut (SSI), Denmark, and Imperial College London have published promising results from the first clinical trial of a vaccine for Chlamydia, the most common sexually transmitted...
12 August 2019 News
The China National Medical Products Administration (NMPA) has approved Gilead Sciences’ Biktarvy, a once-daily single-tablet regimen (STR) to treat HIV-1 infection.
9 August 2019 News
Dynacure has secured orphan drug designation from the US Food and Drug Administration (FDA) for investigational antisense medicine DYN101, which has been designed to modulate the expression of dynamin 2...
6 August 2019 News
Sanofi has announced positive top-line, Phase III results for Dupixent (dupilumab) in children aged six to 11 years old with atopic dermatitis.
6 August 2019 Analysis
This has been a landmark year for HIV treatment; a seven-year study confirmed that taking ART can prevent transmission between gay couples and a second patient has been effectively cured...
1 August 2019 Comment
With a highly effective experimental vaccine to hand, why is Ebola containment proving so difficult?
Given V920’s striking efficacy in preventing Ebola infection and subsequent associated morbidity and mortality, it would stand to reason that Ebola is no longer the threat it was once and...
30 July 2019 News
ViiV Healthcare and Janssen Pharmaceutical have filed separate marketing authorisation applications (MAA) for the use of their respective drugs, cabotegravir and rilpivirine, as a combination therapy in adults with HIV...